Document is current
Any future updates will be listed below
-
Authors
Lee, Younghwan https://orcid.org/0000-0002-0595-1513
Vousden, Karen H. https://orcid.org/0000-0002-7365-1766
Hennequart, Marc
- License Information
-
More Information
Article History
Received: 18 September 2023
Accepted: 30 January 2024
First Online: 2 May 2024
Competing interests
: K.H.V. is on the board of directors, is a shareholder of Bristol Myers Squibb and is on the science advisory board (with stock options) of PMV Pharma, Raze Therapeutics, Volastra Pharmaceuticals and Kovina Therapeutics. She is on the SAB of Ludwig Cancer and is a cofounder and consultant (with stock options) of Faeth Therapeutics. She has received research funding from Astex Pharmaceuticals and AstraZeneca and has contributed to CRUK Cancer Research Technology filing patent application WO/2017/144877. The other authors declare no conflicts of interest.
